EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer

被引：0
作者：
Shuhang Wang
Stella T. Tsui
Christina Liu
Yongping Song
Delong Liu
机构：
[1] Peking University Cancer Hospital,The Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)
[2] SUNY Stony Brook University,Weinberg College of Arts and Sciences
[3] Northwestern University,undefined
[4] Henan Cancer Hospital and the affiliated Cancer Hospital of Zhengzhou University,undefined
来源：
Journal of Hematology & Oncology | / 9卷
关键词：
Epidermal Growth Factor Receptor; Epidermal Growth Factor Receptor Mutant; Anaplastic Lymphoma Kinase; Epidermal Growth Factor Receptor Inhibitor; Epidermal Growth Factor Receptor Gene;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
T790M mutation is the most common mechanism for resistance to first- and second-generation tyrosine kinase inhibitors (TKI) for epidermal growth factor receptor (EGFR). Several third-generation EGFR mutant selective TKIs are being explored to conquer this resistance. AZD9291 (osimertinib, tagrisso) has been approved for treatment of the metastatic EGFR T790M mutation-positive non-small cell lung cancer. Resistance to AZD9291 has been described. C797S mutation was reported to be a major mechanism for resistance to T790M-targeting EGFR inhibitors. This review summarizes the latest development in identifying the C797S mutation and EAI045, the novel selective inhibitor overcoming the C797S mutant.
引用
收藏
相关论文
共 537 条
[1]  
Sharma SV(2007)Epidermal growth factor receptor mutations in lung cancer Nat Rev Cancer 7 169-81
[2]  
Bell DW(2013)The quest to overcome resistance to EGFR-targeted therapies in cancer Nat Med 19 1389-400
[3]  
Settleman J(2009)Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Nature 462 1070-4
[4]  
Haber DA(2014)AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer Cancer Discov 4 1046-61
[5]  
Chong CR(2015)Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI) ASCO Meeting Abstracts 33 8084-9
[6]  
Janne PA(2015)Rociletinib in EGFR-mutated non-small-cell lung cancer N Engl J Med 373 578-9
[7]  
Zhou W(2015)Rociletinib in EGFR-mutated non-small-cell lung cancer N Engl J Med 372 1700-15
[8]  
Ercan D(2013)Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC Cancer Discov 3 1404-99
[9]  
Chen L(2016)Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer J Hematol Oncol 9 34-15
[10]  
Yun CH(2015)AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer N Engl J Med 372 1689-2
12345678910